James Godfrey, M.D.
2020, California State Medical License
2018, Medical Oncology Board Certification
2015, Illinois State Medical License
2015, American Board of Internal Medicine
2008-2012, M.D., The Ohio State University, Columbus, OH
2004-2008, B.S., Biological Sciences. Chapman University, Orange, CA
2015-2018, Clinical Fellow, Department of Hematology and Oncology, University of Chicago, Chicago, IL
2012-2015, Residency, Department of Internal Medicine, The Ohio State University, Columbus, OH
2020-present, Assistant Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2018-2020, Clinical Instructor, Department of Hematology and Oncology, University of Chicago, Chicago, IL
2018, Cancer Research Foundation Young Investigator Award
2018, ASH Research Training Award for Fellows
2018, Janet Rowley University of Chicago Research Day Abstract Award Winner
2017, ASH Clinical Research Training Institute Participant
2017, ASCO Conquer Cancer Foundation Merit Award for Oral Abstract
2017, Adaptive Biotechnologies Young Investigator Award
2014, Clara Bloomfield Award for Excellence in Hematology Research, Ohio State University
2012, Magna Cum Laude, The Ohio State University College of Medicine
2008, Magna Cum Laude, Chapman University
2008, American Physiological Society Award for Excellence in Undergraduate Research
2018-present, Society for Immunotherapy of Cancer
2017-present, American Association for Cancer Research
2015-present, American Society of Clinical Oncology
2015-present, American Society of Hematology
-
Godfrey J and Benson D. The role of natural killer cells in immunity against multiple myeloma. Leuk and Lymphoma. 2012; 53:1666-76.
-
Godfrey J, Bishop MR, Syed S, Hyjek E, and Kline J. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2017; 5:11.
-
Curran EK, Godfrey J, and Kline J. Mechanisms of Immune Tolerance in Leukemia and Lymphoma. Trends Immunol. 2017 Jul;38(7):513-525.
-
Roth, L, Leonard J, Godfrey J, et al. Outcomes of adults and children with primary mediastinal B- cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017 Dec;179(5):739-747.
-
Godfrey J, Smith SM, Hamadani M et al. Autologous versus matched sibling donor or matched unrelated donor allogeneic hematopoietic cell transplantation in follicular lymphoma patients with early chemoimmunotherapy failure: A Center for International Blood and Marrow Transplant Research analysis. Cancer. 2018 Jun;124(12):2541-2551.
-
Godfrey J, Leukam MJ, Smith SM. An update in treating transformed lymphoma. Best Pract Res Clin Haematol. 2018 Sep;31(3):251-261
-
Godfrey J, Nabhan C, Karrison, K, et al. Phase I study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 Jun 1;125(11):1830-1836.
-
Van Slambrouck C, Huh J, Godfrey J, et al. Diagnostic utility of STAT6(YE361) expression in classical Hodgkin lymphoma and related entities. Mod Pathol. 2019 Dec 10.
-
Godfrey J, Tumuluru S, Bao R, et al. PD-L1 gene alterations identify a subset of diffuse large B- cell lymphoma harboring a T cell-inflamed phenotype. Blood. 2019 May 23;133(21):2279-2290.
-
Kline J, Godfrey J, and Ansell S. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020 Feb 20;135(8):523-533.
-
Merryman RW, Carreau NA, Godfrey J, et al. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Oncologist. 2020;25(6):e993-e997.
-
Carreau N, Diefenbach C, Godfrey J, et al. Checkpoint blockade treatment sensitizes relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 Oct;191(1):44-51
-
Carreau N, Diefenbach C, Godfrey J, et al. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Oncologist. 2020 Oct;25(10):878-885.
-
Trujillo J, Godfrey J*, Bishop M, et al. Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 Jun 17;137(24):3454-3459.
-
MacNabb B, Tumuluru S, Godfrey J, et al. Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing. Immunity. 2022 Jun 14;55(6):982-997.
-
Kambhampati S, Mei M, Godfrey J, et al. PD-1 blockade after Avelumab in relapsed/refractory classical Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Oct;22(10):e893-e897.
-
Godfrey J, Liu H, Tallarico M, et al. Pembrolizumab for the treatment of relapsed hematologic malignancies following allogeneic hematopoietic stem cell transplantation. Blood Advances. 2023 Mar 28;7(6):963-970.
-
Song J, Nwangwu, He, Godfrey J, et al. Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma. Haematologica. 2023 Jan 12.
-
Major A, Yu J, Godfrey J, et al. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions. Blood Advances. 2023. In press.
-
Mei M, Chen L, Godfrey J, et al. Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade. Blood. 2023. In press.
-
Godfrey J*, Chen X, Sunseri N, et al. TIGIT is a key inhibitory checkpoint receptor in lymphoma. JITC. In press.
-
Godfrey J, Mei M, Chen L, et al. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma. Haematologica. In press.
-
Ong S, Pak S, Mei M, Godfrey, et al. Bendamustine is a well-tolerated alternative to fludarabine as lymphodepletion for chimeric antigen receptor (CAR) T-cell therapy. American Journal of Hematology. In press